MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Wang et al. evaluated the global warming potential of various greenhouse gases used in medical practice, analyzing both their clinical applications and environmental effects. The study identified anesthetic agents such as desflurane and nitrous oxide, as well as fluorinated gases used in retinal surgery, as particularly problematic due to their exceptionally high global warming potential and prolonged atmospheric persistence. The authors advocate for targeted interventions to reduce the environmental footprint of medical gases while maintaining clinical effectiveness.

On May 13, 2025, the Common Package of Benefits of the Spanish National Health System (NHS) was amended. The med tech-related updates mostly concerned in-vitro diagnostics, gastrointestinal, e-Health, cardiovascular, ENT, ophthalmology, oral health, and neurology fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Hogervorst et al. conducted a systematic literature review to map analytical methods used for comparing uncontrolled trials with external controls derived from real-world data. The authors benchmarked these approaches against European regulatory and HTA practices. The review, encompassing European agency guidelines and assessment reports, revealed a lack of alignment between state-of-the-art methodological recommendations and their practical application in regulatory and HTA decision-making. The authors propose twelve actionable recommendations to bridge these methodological gaps and enhance transparency in the use of real-world data.

In May 2025, the Dutch Organization for Health Research and Development (ZonMw) opened the submission of grant applications for the subsidy round of the Appropriate Care Framework program (2024–2028), which focuses on (de)implementation activities for medical technologies reimbursed under basic health insurance. The deadline for submitting a detailed grant application is July 3, 2025.

On May 8, 2025, the Medical Technologies Product (MTP) Council revised its recommendations on continuous glucose monitoring (CGM) for patients with type 2 diabetes (T2D), initially issued in 2022 under the Orderly Introduction of Medical Technologies framework. The updated recommendations now allow the use of other CGM devices considered equivalent to FreeStyle Libre and FreeStyle Libre 2, which were the only recommended products in 2022. Simultaneously, the MTP Council initiated a reassessment of CGM devices for T2D and tasked the Dental and Pharmaceutical Benefits Agency (TLV) to carry out a new health economic evaluation.

On May 5, 2025, the Belgian Health Care Knowledge Centre (KCE) opened its annual call for topic proposals for the 2026 research program, which includes Clinical Guidelines, Health Technology Assessments, and Health Services Research. Interested stakeholders can submit the proposals by June 30, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Wang et al. conducted a survey and multi-stakeholder workshop to assess the readiness and strategic approaches of pharmaceutical companies regarding the Joint Clinical Assessment (JCA) under the new European HTA Regulation. Thirteen companies took part, reporting moderate preparedness for the JCA process (with readiness scores of 6–7 out of 10), but expressing concerns about uncertain timelines and challenges in integrating JCA outcomes into national processes. To support effective JCA implementation in national HTA decisions, the authors recommend creating a product-based scorecard for submission quality, increasing member state training, and promoting ongoing dialogue among key stakeholders.

In May 2025, the evaluation phase of the “New Methods” framework was completed for three technologies: leadless pacemaker for cardiac arrhythmias, MR-guided focused ultrasound for essential tremor, and Electrical Field Therapy for glioblastoma treatment. As the recommendations from HTA are now available, the Decision Forum needs to make coverage decisions for these technologies.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Senior Evidence Synthesis Specialist.

MTRC, a leading boutique Med Tech market access consultancy in Europe, is looking for a Director of Evidence Synthesis to lead our growing evidence synthesis function.

MTRC is pleased to announce the release of its latest White Paper: "Transitional Coverage of Innovative Medical Devices in France (pre-LPPR)". This White Paper is designed for medical device manufacturers, market access experts, and health policy leaders who are shaping strategies for early adoption in the French market.

MTRC is pleased to announce the release of its latest White Paper: "Evidence requirements for the creation of IVD reimbursement (NABM) codes in France". This document sheds light on the broader evidence requirements and decision-making framework used by HAS, offering diagnostics manufacturers critical insights into the expectations and potential challenges of securing NABM reimbursement.